Consequently, an inhibition of Pin1 expression can contribute to a significant reduction in androgen receptor transcriptional activities, and thus combined treatment with a Pin1 inhibitor and ralaniten leads to cell cycle arrest, thereby serving as an antitumor strategy against castration-resistant prostate cancer xenografts (40). The gene discussed is AR; the disease is prostate carcinoma.